NCT07321977 Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers
| NCT ID | NCT07321977 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut de Myologie, France |
| Condition | Spinal Muscular Atrophy (SMA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-03-03 |
| Primary Completion | 2026-07-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-03-03 with a primary completion date of 2026-07-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Current gait tests only consider the time factor and not the evolution of the patient's biomechanics, which may prove insufficient for patients whose symptoms generally progress slowly. Quantifying gait parameters in neuromuscular patients therefore appears necessary. This is why we propose to study markerless gait analysis in this population, which would allow for simple and effective monitoring of kinematic parameters without resorting to complex equipment incompatible with routine clinical practice.
Eligibility Criteria
* All volunteers * Age between 18 and 65 * Ambulatory * Informed consent to participate in the study * Member of or beneficiary of a social security system * Volunteers with a neuromuscular disease * Confirmed diagnosis of a neuromuscular disease of genetic origin (medical document to be provided upon enrollment in the study with proof of diagnosis) belonging to the list above. * Ability to walk for 2 minutes without assistance. * Ability to stand up from a chair with armrests at least 3 times in 30 seconds. * Ability to climb an inclined plane independently or with assistance to access the movement analysis room. Exclusion Criteria * All volunteers * Individuals under guardianship, curatorship, or legal protection * Pregnant or breastfeeding women * Non-ambulatory individuals * Individuals with epilepsy * Skin conditions preventing the placement of VICON motion sensors * Asymptomatic volunteers * Unstable respiratory or cardiac problems * Neurological, musculoskeletal, or psychiatric problems * Volunteers with a neuromuscular disease * Recent trauma or serious falls (≤ 6 months) * Individuals who have fallen more than twice in the past year and at least once in the past three months * Use of assistive devices such as rigid knee braces or walkers * Unstable cardiomyopathy * Individuals awaiting diagnosis Exclusion criteria * Inability to comply with the protocol requirements * Medical or social conditions that could interfere with the study, as determined by the coordinating investigator or co-investigators.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07321977 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Spinal Muscular Atrophy (SMA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07321977 currently recruiting?
Yes, NCT07321977 is actively recruiting participants. Contact the research team at p.santmarty@institut-myologie.org for enrollment information.
Where is the NCT07321977 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT07321977 clinical trial?
NCT07321977 is sponsored by Institut de Myologie, France. The trial plans to enroll 30 participants.